ISP 2008

2nd International Symposium

on Pheochromocytoma

 

17th - 20th September 2008

Queens' College, Cambridge, UK

 Mathematical Bridge, Queens' College Cambridge
 

HomeOrganising CommitteesScientific ProgrammeVenue & Social EventsPatients ProgrammeRegistration
Abstract SubmissionContact UsLinks
 
 

 

Scientific Programme

 

Target Audience

Scientists, physicians, radiologists, pathologists, nuclear medicine physicians and other healthcare professionals (e.g., genetic counsellors, nurses) working in the fields of endocrinology, oncology, hypertension, genetics or with specific interests in basic or clinical research about catecholamine-producing tumours.

The symposium is also open to patients, their family members, and patient support group representatives.

Accreditation

The Organisers will apply for Continuing Professional Development accreditation from the Royal College of Physicians of London.

 
 

Fitzpatrick Lecture Hall, Queens' College Cambridge
 

Educational Objectives

Participants will learn about the latest scientific discoveries and advances in genetics, diagnosis, localisation and pathogenesis of pheochromocytomas and paragangliomas, and the management and treatment of patients with these tumours.

 Poster Exhibition
   
Provisional Programme
Wednesday 17th September 2008
17.00 – 20.00     Registration
19.00 – 19.40     Session 1 – Clinical Background
19.00 – 19.40 1.1   Opening Lecture:
The protean manifestations of pheochromocytoma
William Manger (USA)
20.00 – 21.30     Welcome Reception and Buffet Supper
       
Thursday 18th September 2008
09.00 – 09.15     Welcome and introduction
      Morris Brown (UK) and Ashley Grossman (UK)
09.15 – 10.45     Session 2 – Tumour Biology
      Chair: Arthur Tischler (USA)
09.15 – 09.35 2.1   The genetic landscape of pheochromocytoma: an update
Patricia Dahia (USA)
09.35 – 09.40     Discussion
09.40 – 10.00 2.2   The HIF pathway and VHL
William Kaelin (USA)
10.00 – 10.05     Discussion
10.05 – 10.25 2.3   The biology of oxygen sensing
Peter Radcliffe (UK)
10.25 – 10.30     Discussion
10.30 – 10.40 2.4   Conditional PTEN knock-out mice: a model for malignant pheochromocytomas
Korpershoek E1, Loonen AJM1, Corvers S1, van Nederveen FH1, Jonkers J2, Ma X1, Ziel-van der Made A1, Korsten H1, Trapman J1, Dinjens WNM1, de Krijger RR1
10.40 – 10.45     Discussion
10.45 – 11.15     COFFEE
11.15 – 12.50     Session 3 - Biochemical Diagnosis
      Chair: Graeme Eisenhofer (Germany)
11.15 – 11.30 3.1   Overview
Graeme Eisenhofer (Germany)
11.30 – 11.45 3.2   LC/MS assay for plasma metanephrines
Ido Kema (The Netherlands)
11.45 – 11.50     Discussion
11.50 – 12.05 3.3   Dynamic testing
Jacques Lenders (The Netherlands)
12.05 – 12.10     Discussion
12.10 – 12.30 3.4   New essays for metanephrines
Stephan Petersen (Germany)
12.30 – 12.35     Discussion
12.35 – 12.45 3.5   The advantage of measuring free and sulphate-conjugated metanephrines in blood for the diagnosis of pheochromocytoma
Drouard-Troalen L1, Buclin T2, Baudin E3, Plouin PF4, Muller B5, Ruffieux C6, Grand D2, Grouzmann E2
     
1Department of Clinical Biology,Institut Gustave-Roussy, Villejuif, France, 2Division of Clinical Pharmacology and Toxicology, University Hospital, Lausanne, Lausanne, Switzerland, 3Department of Radiology,Institut Gustave-Roussy, Villejuif, France, 4Hypertension Unit, Hôpital Européen Georges Pompidou, Paris, France, 5Kantonsspital, Aaran 5001, Switzerland, 6Institute of Social and Preventive Medicine,University Hospital, Lausanne, Lausanne, Switzerland
12.45 – 12.50     Discussion
12.50 – 13.45     LUNCH
13.45 – 15.15     Session 4 - Case-based discussion of imaging
      Chair: Ashley Grossman (UK)
13.45 – 14.05 4.1   The role of CT and MRI
Rodney Reznek (UK)
14.05 – 14.10     Discussion
14.10 – 14.30 4.2   123I-MIBG - isotope scanning 
      Val Lewington (UK)
14.30 – 14.35     Discussion
14.35 – 14.55 4.3   PET scanning
Karen Pacak (USA)
14.55 – 15.00     Discussion
15.00 – 15.10 4.4   Head to head comparison of 18F-fluoro-L-DOPA, 18F-fluorodopamine and 18F-fluoro-deoxyglucose PET, and 123I-metaiodobenzylguanidine scintigraphy in the localization of benign and malignant pheochromocytoma and extra-adrenal paraganglioma
Timmers HJLM1, Chen CC2, Carrasquillo JA2, Whatley M2, Ling A2, Eisenhofer G2, Martiniova L2, Adams KT2, Pacak K2
1Radboud Universtity Nijmegen Medical Centre, Nijmegen, Netherlands, 2National Institutes of Health, Bethesda, MD, USA
15.10 – 15.15     Discussion
15.15 – 15.45     TEA
15.45 – 17.45     Satellite Symposium
      New Advances in Therapy for Malignant Pheochromocytoma and Paraganglioma
sponsored by Molecular Insight Pharmaceuticals, Inc.
      Chair: Karel Pacak (USA)
       
      Introductory overview on the therapy of malignant pheochromocytomas and paragangliomas
Hendrik Lehnert (UK)
       
      New developments in radiolabelled 131I-MIBG therapy
Edward Coleman (USA)
       
      Current experience with combining targeted radiotherapy with radiosensitizers and chemotherapy
Mark Gaze (UK)
       
      Molecular targeted therapy
Camilo Jimenez (USA)
       
      Summary and Panel Discussion
17.45 – 19.15     Poster Session
Including drinks reception
19.30 – 20.30     Musical Recital, Queens' College Chapel
20.30 –     Dinner, Cripps Hall
       
Friday 19th September 2008
09.00 – 10.30     Session 5 - Germline Syndromes
      Chair: Patricia Dahia (USA)
09.00 – 09.20 5.1   Paraganglioma syndromes - clinical aspects
      Henri Timmers (The Netherlands)
09.20 – 09.25     Discussion
09.25 – 09.45 5.2   Paraganglioma syndromes - genetic aspects
      Anne-Paule Gimenez-Roqueplo (France)
09.45 – 09.50     Discussion
09.50 – 10.10 5.3   MEN-2 and VHL
      Bruce Robinson (Australia)
10.10 – 10.15     Discussion
10.15 – 10.25 5.4   Functional study in a yeast model of a novel SDHB germline missense mutation (C191Y) diagnosed in a patient affected by a glomus tumor
Goffrini P1, Ercolino T2, Dima V1, Mannelli M2, Ferrero I1
     
1Department of Genetics, Biology of Microrganisms, Anthropology and Evolution, University of Parma, Parma, Italy, 2Department of Clinical Pathophysiology, University of Florence, Firenze, Italy
10.25 – 10.30     Discussion
10.30 – 11.00     COFFEE
11.00 – 12.30     Session 6 - Free Communications
      Chair: Stephen Ball (UK)
11.00 - 11.12 6.1   Warburg effect in VHL-related pheochromocytomas. A HIF and p53-mediated metabolic switch?
Favier J1, Brière JJ2, Plouin PF4, Bertherat J3, Jeunemaitre X1, Rustin P2, Gimenez-Roqueplo AP1
     
1INSERM, unit 772, Paris, France, 2INSERM, unit 676, Paris, France, 3AP-HP, Hôpital Cochin, Département d'Endocrinologie, Paris, France, 4AP-HP, Hôpital Européen Georges Pompidou, Service d'Hypertension artérielle, Paris, France
11.12 - 11.15     Discussion
11.15 - 11.27 6.2   The genetics of pheochromocytoma and paraganglioma in Italy: results of the Italian Pheo/PGL Network
Mannelli M1, Opocher G2, Castellano M3, Ercolino T1, Giachè V1, Schiavi F2, Pignataro V2, Mori L3, Giacchè M3
     
1Dept. Clinical Pathophysiology, Univ. Florence, Florence, Italy, 2Dept. of Medical and Surgical Sciences, University of Padua, Padua, Italy, 3Dept. of Medical and Surgical Sciences, University of Brescia, Brescia, Italy
11.27 - 11.30     Discussion
11.30 - 11.42 6.3   Glucocorticoids may induce pheochromocytoma crises
Rosas A L1, Kasperlik-Zaluska A A2, Papierska L2, Bass B L3, Pacak K4, Eisenhofer G5
      1The Methodist Hospital, Department of Anesthesiology, Houston, Texas, USA, 2Department of Endocrinology, Center for Postgraduate Medical Education, Warsaw, Poland, 3The Methodist Hospital, Department of Surgery, Houston, Texas, USA, 4Pediatric and Reproductive Endocrinology Branch, National Institutes of Health, Bethesda, Maryland, USA, 5Institute of Clinical Chemistry and Laboratory Medicine and Department of Medicine, University of Dresden, Dresden, Germany
11.42 - 11.45     Discussion
11.45 - 11.57 6.4   Origin and spread of "epidemic paraganglioma" in Trentino
Schiavi F1, Demattè S2, Portolan F2, Cecchini ME2, Del Piano A2, Barollo S3, Vianello B3, Pignataro V4, Boaretto F4, Colombo R5, Opocher G1
     
1Familial Cancer Clinic, Veneto Institute of Oncology IRCCS, Padova, Italy, 2Internal Medicine, S.Chiara, Trento, Italy, 3Endocrinology, University of Padova, Padova, Italy, 4Biology, University of Padova, Padova, Italy, 5Human Molecular Biology and Genetics, Catholic University of the Sacred Heart, Milano, Italy
11.57 - 12.00     Discussion
12.00 - 12.12 6.5   Low penetrance and variable phenotype of a new SDHB mutation with a founder effect associated to pheochromocytoma-paraganglioma
Castellano M, Agliozzo E, Giacchè M, Mori L, Cherubini L, Panarotto A, Cappelli C, Agabiti Rosei E

Molecular Medicine Laboratory and Endocrinology Unit. Brescia University Medical School, Brescia, Italy
12.12 - 12.15     Discussion
12.15 - 12.27 6.6   Clinical utility of temozolomide (Temodar) in the treatment of malignant paraganglioma: a preliminary report
Bravo EL

Cleveland Clinic, Dept. of Nephrology/Hypertension, Glickman Urological & Kidney Institute, Cleveland, Ohio, USA
12.27 - 12.30     Discussion
12.30 – 13.30     LUNCH
13.30 – 15.30     Session 7 - Management
      Chair: Morris Brown (UK)
13.30 – 13.50 7.1   Surgical options
      Martin Walz (Germany)
13.50 – 14.10 7.2   Adrenal sparing
      Speaker to be confirmed
14.10 – 14.30     Panel discussion
14.30 – 14.50 7.3   The future for pathology in recognising malignancy
      Noriko Kimura (Japan)
14.50 – 15.00     Discussion
15.00 – 15.30     TEA
15.30 – 17.30     Session 8 - Parallel Workshop Sessions
      Session 8a                 Biochemical screening techniques
      Chairs: Ravinder Singh (USA)
                  Robert Peaston (UK) 
      Session 8b                 Optimal imaging strategy
      Chairs: Val Lewington (UK)
                  Adrian Dixon (UK) 
      Session 8c                 Genetic screening
      Chairs: Massimo Mannelli (Italy)
                  Krish Chatterjee (UK) To be confirmed 
      Session 8d                 Management strategy
      Chairs: Hakan Ahlman (Sweden)
                  Pierre-Francois Plouin (France) 
18.30 – 20.00     Poster Session
      Including drinks reception
20.00 – 22.30     Symposium Gala Dinner, Cripps Hall
       
Saturday 20th September 2008
09.00 – 10.30     Session 9 - Debate & General Discussion
      Chair: Emmanuel Bravo (USA)
      'It is cost effective for every patient under 50 years to have genetic screening'
09.00 – 09.20     For:                     Mercedes Robledo (Spain)
09.20 – 09.40     Against:                Zoran Erlic (Germany)/Hartmut Neumann (Germany)
09.40 – 10.00     Discussion/Consensus
      Co-chairs: Morris Brown (UK) and Ashley Grossman (UK)
10.00 – 10.30     General discussion on parallel sessions 8a, 8b, 8c, 8d
10.30 – 11.00     COFFEE
11.00 – 12.00     Session 10 - Research Studies/Future Plans
      Chair: Karel Pacak (USA)
12.00 - 12.30     PRESSOR Business Meeting
Discussion about ISP 2011
Official Close of Symposium
12.00 – 14.00     LUNCH